Patents Assigned to Genentech
  • Patent number: 7736645
    Abstract: The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Also provided herein are methods of screening for modulators of EG-VEGF. Furthermore, methods and related methods of treatment are described herein which pertain to regulating cellular proliferation and chemotaxis.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: June 15, 2010
    Assignee: Genentech, Inc.
    Inventors: Napoleone Ferrara, Colin Watanabe, William I. Wood, Theresa Shek
  • Patent number: 7737259
    Abstract: Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.
    Type: Grant
    Filed: November 30, 2006
    Date of Patent: June 15, 2010
    Assignee: Genentech, Inc.
    Inventors: Yvonne M. Chen, Anan Chuntharapai, Dimitry Danilenko, Wenjun Ouyang, Susan Sa, Patricia Valdez, Terence Wong, Jianfeng Wu, Yan Zheng
  • Publication number: 20100143352
    Abstract: The invention provides methods of treating B cell based malignancies and B-cell regulated autoimmune disorders using a combination therapy of anti-CD20 antibody with a BLyS antagonist.
    Type: Application
    Filed: November 24, 2009
    Publication date: June 10, 2010
    Applicant: Genentech, Inc.
    Inventors: Andrew Chan, Qian Gong, Flavius Martin
  • Publication number: 20100145027
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: February 8, 2010
    Publication date: June 10, 2010
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Dan L. Eaton, Audrey Goddard, Austin L. Gurney, William I. Wood, Thomas D. Wu
  • Publication number: 20100143351
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human subjects susceptible to or diagnosed with breast cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: November 20, 2009
    Publication date: June 10, 2010
    Applicant: Genentech, Inc.
    Inventors: Gwendolyn Fyfe, See Chun Phan, Xian Zhou
  • Patent number: 7732567
    Abstract: Methods and compositions for use in modulating the activity(s) of WISP-1 polypeptide are provided. WISP-1 antagonists include anti-WISP-1 antibodies, WISP-1 immunoadhesins and WISP-1 variants (and fusion proteins thereof) which inhibit or neutralize induction or secretion of HAS2, HA, CD44 or RHAMM by native human WISP-1 polypeptide in at least one type of mammalian cell. The invention also provides methods for in vitro, in situ, and/or in vivo diagnosis and/or treatment of mammalian cells or pathological conditions associated with native WISP-1 polypeptides.
    Type: Grant
    Filed: October 20, 2008
    Date of Patent: June 8, 2010
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Ellen Filvaroff
  • Publication number: 20100136005
    Abstract: Humanized anti-CD11a antibodies and various uses therefor are disclosed. The humanized anti-CD11a antibody may bind specifically to human CD11a I-domain, have an IC50(nM) value of no more than about 1 nM for preventing adhesion of Jurkat cells to normal human epidermal keratinocytes expressing ICAM-1, and/or an IC50 (nM) value of no more than about 1 nM in the mixed lymphocyte response assay.
    Type: Application
    Filed: November 23, 2009
    Publication date: June 3, 2010
    Applicant: Genentech, Inc.
    Inventors: Paula M. Jardieu, Leonard G. Presta
  • Publication number: 20100136580
    Abstract: The invention provides modulators of Dvl PDZ-ligand interaction, and methods of identifying and using these modulators.
    Type: Application
    Filed: January 29, 2010
    Publication date: June 3, 2010
    Applicant: Genentech, Inc.
    Inventors: Yingnan Zhang, Mike Costa, Sachdev S. Sidhu
  • Publication number: 20100136624
    Abstract: A method of making monoclonal antibodies according to a mixed antigen immunization protocol is described. In addition, antibodies obtainable by the method are disclosed which specifically cross-react with two or more different receptors to which Apo-2 ligand (Apo-2L) can bind.
    Type: Application
    Filed: July 30, 2009
    Publication date: June 3, 2010
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Anan Chuntharapai, K. Jin Kim
  • Patent number: 7727536
    Abstract: The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Also provided herein are methods of screening for modulators of EG-VEGF. Furthermore, methods and related methods of treatment are described herein which pertain to regulating cellular proliferation and chemotaxis.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: June 1, 2010
    Assignee: Genentech, Inc.
    Inventors: Napoleone Ferrara, Colin Watanabe, William I. Wood
  • Patent number: 7727533
    Abstract: Described is a family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family is STEAP-1, which appears to be a type IIIa membrane protein. STEAP-1 is a 339 amino acid protein. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: June 1, 2010
    Assignee: Genentech, Inc.
    Inventors: Daniel E. Afar, Rene S. Hubert, Arthur B. Raitano, Douglas Saffran, Steven Chappell Mitchell
  • Patent number: 7727527
    Abstract: The present invention relates generally to methods of using anti-NGF antibodies in the treatment of various NGF-related disorders, including asthma, arthritis and psoriasis. The methods are effective in treating these disorders in a patient without having a significant adverse effect on the immune system of the patient.
    Type: Grant
    Filed: May 9, 2002
    Date of Patent: June 1, 2010
    Assignee: Genentech, Inc.
    Inventor: David L. Shelton
  • Patent number: 7728108
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: June 1, 2010
    Assignee: Genentech Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Colin K. Watanabe, William I. Wood
  • Publication number: 20100129375
    Abstract: The present invention provides methods of using TSPAN12 and Norrin antagonists to inhibit ocular vascular development and to treat related disorders.
    Type: Application
    Filed: September 10, 2009
    Publication date: May 27, 2010
    Applicant: Genentech, Inc.
    Inventors: Harald J. Junge, Weilan Ye
  • Publication number: 20100130539
    Abstract: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein Q, X1, X2, Y, Z R1, R2, R3, R3?, R4, R4?, R5, R6, R6? and n are as described herein.
    Type: Application
    Filed: December 14, 2007
    Publication date: May 27, 2010
    Applicant: Genentech Inc.
    Inventor: Michael F.T. Koehler
  • Publication number: 20100129356
    Abstract: The present invention provides methods of using a DLL4 modulator to modulate vascular development. Furthermore, methods of treatment using DLL4 modulators, such as DLL4 antagonists, are provided.
    Type: Application
    Filed: July 2, 2009
    Publication date: May 27, 2010
    Applicant: GENENTECH, INC.
    Inventor: MINHONG YAN
  • Publication number: 20100129381
    Abstract: The invention provides anti-FGF19 antibodies, and compositions comprising and methods of using these antibodies, methods using anti-FGF19 antibodies, and methods comprising detection of FGF19 and/or FGFR4.
    Type: Application
    Filed: January 22, 2010
    Publication date: May 27, 2010
    Applicant: Genentech, Inc.
    Inventors: Luc DESNOYERS, Dorothy French
  • Patent number: 7723488
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 21, 2004
    Date of Patent: May 25, 2010
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Ellen Filvaroff, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Patent number: 7723485
    Abstract: Cysteine engineered anti-MUC16 antibodies are engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-MUC16 antibodies are provided. Cysteine engineered anti-MUC16 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-MUC16 antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: May 25, 2010
    Assignee: Genentech, Inc.
    Inventors: Jagath R. Junutula, William Mallet
  • Patent number: 7723330
    Abstract: Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: May 25, 2010
    Assignees: Array BioPharma Inc., Genentech, Inc.
    Inventors: James F. Blake, Steven Armen Boyd, Jason De Meese, Kin Chiu Fong, John J. Gaudino, Tomas Kaplan, Allison L. Marlow, Jeongbeob Seo, Allen A. Thomas, Hongqi Tian, Frederick Cohen, Wendy B. Young